http://142-54-23-223.fusionmedialtd.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Fri, 14 Aug 2026 08:52:00 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://142-54-23-223.fusionmedialtd.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/SEC+Filings/Form++S-8++++++++DELCATH+SYSTEMS%2C+INC.++++++++++++++++/26925385.html si-local-file:///var/storage/secattach/20260814/26925385.html http://www.streetinsider.com/SEC+Filings/Form++S-8++++++++DELCATH+SYSTEMS%2C+INC.++++++++++++++++/26925385.html Fri, 14 Aug 2026 08:52:00 -0400 DCTH O.02931219 http://www.streetinsider.com/SEC+Filings/Form++S-8++++++++DELCATH+SYSTEMS%2C+INC.++++++++++++++++/26925385.html si-local-file:///var/storage/secattach/20260814/26925385.html http://www.streetinsider.com/SEC+Filings/Form++S-8++++++++DELCATH+SYSTEMS%2C+INC.++++++++++++++++/26925385.html Fri, 14 Aug 2026 08:52:00 -0400 DCTH O.02931219 http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++DELCATH+SYSTEMS%2C+INC.+++++For%3A+Aug+12/26924963.html si-local-file:///var/storage/secattach/20260814/26924963.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++DELCATH+SYSTEMS%2C+INC.+++++For%3A+Aug+12/26924963.html Fri, 14 Aug 2026 08:10:00 -0400 DCTH O.02931219 http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++DELCATH+SYSTEMS%2C+INC.+++++For%3A+Aug+12/26924963.html si-local-file:///var/storage/secattach/20260814/26924963.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++DELCATH+SYSTEMS%2C+INC.+++++For%3A+Aug+12/26924963.html Fri, 14 Aug 2026 08:10:00 -0400 DCTH O.02931219 http://www.streetinsider.com/SEC+Filings/Form++10-Q+++++++DELCATH+SYSTEMS%2C+INC.+++++For%3A+Jun+30/26880519.html si-local-file:///var/storage/secattach/20260806/26880519.html http://www.streetinsider.com/SEC+Filings/Form++10-Q+++++++DELCATH+SYSTEMS%2C+INC.+++++For%3A+Jun+30/26880519.html Thu, 06 Aug 2026 09:10:00 -0400 DCTH O.02931219 http://www.streetinsider.com/SEC+Filings/Form++10-Q+++++++DELCATH+SYSTEMS%2C+INC.+++++For%3A+Jun+30/26880519.html si-local-file:///var/storage/secattach/20260806/26880519.html http://www.streetinsider.com/SEC+Filings/Form++10-Q+++++++DELCATH+SYSTEMS%2C+INC.+++++For%3A+Jun+30/26880519.html Thu, 06 Aug 2026 09:10:00 -0400 DCTH O.02931219 http://www.streetinsider.com/Earnings/Delcath+Systems+%28DCTH%29+Tops+Q2+EPS+by+17c/26879533.html <p>Delcath Systems (NASDAQ: DCTH) reported Q2 EPS of $0.07, $0.17 better than the analyst estimate of ($0.10). Revenue for the quarter came in at $29.1 million versus the consensus estimate of $26.6 million.</p><p>For earnings history and earnings-related data on Delcath Systems (DCTH) <a href="http://www.streetinsider.com/ec_earnings.php?q=DCTH">click here</a>.</p> http://www.streetinsider.com/Earnings/Delcath+Systems+%28DCTH%29+Tops+Q2+EPS+by+17c/26879533.html Thu, 06 Aug 2026 08:16:21 -0400 DCTH http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++DELCATH+SYSTEMS%2C+INC.+++++For%3A+Aug+06/26879456.html si-local-file:///var/storage/secattach/20260806/26879456.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++DELCATH+SYSTEMS%2C+INC.+++++For%3A+Aug+06/26879456.html Thu, 06 Aug 2026 08:10:00 -0400 DCTH O.02931219 http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++DELCATH+SYSTEMS%2C+INC.+++++For%3A+Aug+06/26879456.html si-local-file:///var/storage/secattach/20260806/26879456.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++DELCATH+SYSTEMS%2C+INC.+++++For%3A+Aug+06/26879456.html Thu, 06 Aug 2026 08:10:00 -0400 DCTH O.02931219 http://www.streetinsider.com/Press+Releases/Delcath+Systems+Reports+Second+Quarter+2026+Results+and+Business+Highlights/26879259.html <p class="bwalignc"> <i>Increases 2026 Revenue Guidance to a Range of $104M to $108M <br></br></i><i>Conference Call Today at 8:30 a.m. Eastern Time</i> </p> <p> QUEENSBURY, N.Y.--(BUSINESS WIRE)-- Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic liver cancers, today announced financial results and business highlights for the second quarter ended June 30, 2026. </p><p> <b>Second Quarter 2026 Financial Results</b> </p><ul class="bwlistdisc"> <li> Total revenue of $29.1 million, compared with $24.2 million in the second quarter of 2025 <ul class="bwlistcircle"> <li> HEPZATO KIT™ revenue of $27.1 million, compared to $22.5 million in the second quarter of 2025 </li> <li> CHEMOSAT® revenue of $2.0 million, compared to $1.7 http://www.streetinsider.com/Press+Releases/Delcath+Systems+Reports+Second+Quarter+2026+Results+and+Business+Highlights/26879259.html Thu, 06 Aug 2026 08:01:00 -0400 A.09642568 DCTH O.02931219 O.20371933 http://www.streetinsider.com/Press+Releases/Delcath+Systems+Reports+Second+Quarter+2026+Results+and+Business+Highlights/26879259.html <p class="bwalignc"> <i>Increases 2026 Revenue Guidance to a Range of $104M to $108M <br></br></i><i>Conference Call Today at 8:30 a.m. Eastern Time</i> </p> <p> QUEENSBURY, N.Y.--(BUSINESS WIRE)-- Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic liver cancers, today announced financial results and business highlights for the second quarter ended June 30, 2026. </p><p> <b>Second Quarter 2026 Financial Results</b> </p><ul class="bwlistdisc"> <li> Total revenue of $29.1 million, compared with $24.2 million in the second quarter of 2025 <ul class="bwlistcircle"> <li> HEPZATO KIT™ revenue of $27.1 million, compared to $22.5 million in the second quarter of 2025 </li> <li> CHEMOSAT® revenue of $2.0 million, compared to $1.7 http://www.streetinsider.com/Press+Releases/Delcath+Systems+Reports+Second+Quarter+2026+Results+and+Business+Highlights/26879259.html Thu, 06 Aug 2026 08:01:00 -0400 A.09642568 DCTH O.02931219 O.20371933 http://www.streetinsider.com/Press+Releases/Delcath+Systems+Reports+Second+Quarter+2026+Results+and+Business+Highlights/26879259.html <p class="bwalignc"> <i>Increases 2026 Revenue Guidance to a Range of $104M to $108M <br></br></i><i>Conference Call Today at 8:30 a.m. Eastern Time</i> </p> <p> QUEENSBURY, N.Y.--(BUSINESS WIRE)-- Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic liver cancers, today announced financial results and business highlights for the second quarter ended June 30, 2026. </p><p> <b>Second Quarter 2026 Financial Results</b> </p><ul class="bwlistdisc"> <li> Total revenue of $29.1 million, compared with $24.2 million in the second quarter of 2025 <ul class="bwlistcircle"> <li> HEPZATO KIT™ revenue of $27.1 million, compared to $22.5 million in the second quarter of 2025 </li> <li> CHEMOSAT® revenue of $2.0 million, compared to $1.7 http://www.streetinsider.com/Press+Releases/Delcath+Systems+Reports+Second+Quarter+2026+Results+and+Business+Highlights/26879259.html Thu, 06 Aug 2026 08:01:00 -0400 A.09642568 DCTH O.02931219 O.20371933 http://www.streetinsider.com/Press+Releases/Delcath+Systems+Reports+Second+Quarter+2026+Results+and+Business+Highlights/26879259.html <p class="bwalignc"> <i>Increases 2026 Revenue Guidance to a Range of $104M to $108M <br></br></i><i>Conference Call Today at 8:30 a.m. Eastern Time</i> </p> <p> QUEENSBURY, N.Y.--(BUSINESS WIRE)-- Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic liver cancers, today announced financial results and business highlights for the second quarter ended June 30, 2026. </p><p> <b>Second Quarter 2026 Financial Results</b> </p><ul class="bwlistdisc"> <li> Total revenue of $29.1 million, compared with $24.2 million in the second quarter of 2025 <ul class="bwlistcircle"> <li> HEPZATO KIT™ revenue of $27.1 million, compared to $22.5 million in the second quarter of 2025 </li> <li> CHEMOSAT® revenue of $2.0 million, compared to $1.7 http://www.streetinsider.com/Press+Releases/Delcath+Systems+Reports+Second+Quarter+2026+Results+and+Business+Highlights/26879259.html Thu, 06 Aug 2026 08:01:00 -0400 A.09642568 DCTH O.02931219 O.20371933 http://www.streetinsider.com/Business+Wire/Delcath+Systems+Reports+Second+Quarter+2026+Results+and+Business+Highlights/26879259.html <p class="bwalignc"> <i>Increases 2026 Revenue Guidance to a Range of $104M to $108M <br></br></i><i>Conference Call Today at 8:30 a.m. Eastern Time</i> </p> <p> QUEENSBURY, N.Y.--(BUSINESS WIRE)-- Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic liver cancers, today announced financial results and business highlights for the second quarter ended June 30, 2026. </p><p> <b>Second Quarter 2026 Financial Results</b> </p><ul class="bwlistdisc"> <li> Total revenue of $29.1 million, compared with $24.2 million in the second quarter of 2025 <ul class="bwlistcircle"> <li> HEPZATO KIT™ revenue of $27.1 million, compared to $22.5 million in the second quarter of 2025 </li> <li> CHEMOSAT® revenue of $2.0 million, compared to $1.7 http://www.streetinsider.com/Business+Wire/Delcath+Systems+Reports+Second+Quarter+2026+Results+and+Business+Highlights/26879259.html Thu, 06 Aug 2026 08:01:00 -0400 A.09642568 DCTH O.02931219 O.20371933 http://www.streetinsider.com/Business+Wire/Delcath+Systems+Reports+Second+Quarter+2026+Results+and+Business+Highlights/26879259.html <p class="bwalignc"> <i>Increases 2026 Revenue Guidance to a Range of $104M to $108M <br></br></i><i>Conference Call Today at 8:30 a.m. Eastern Time</i> </p> <p> QUEENSBURY, N.Y.--(BUSINESS WIRE)-- Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic liver cancers, today announced financial results and business highlights for the second quarter ended June 30, 2026. </p><p> <b>Second Quarter 2026 Financial Results</b> </p><ul class="bwlistdisc"> <li> Total revenue of $29.1 million, compared with $24.2 million in the second quarter of 2025 <ul class="bwlistcircle"> <li> HEPZATO KIT™ revenue of $27.1 million, compared to $22.5 million in the second quarter of 2025 </li> <li> CHEMOSAT® revenue of $2.0 million, compared to $1.7 http://www.streetinsider.com/Business+Wire/Delcath+Systems+Reports+Second+Quarter+2026+Results+and+Business+Highlights/26879259.html Thu, 06 Aug 2026 08:01:00 -0400 A.09642568 DCTH O.02931219 O.20371933 http://www.streetinsider.com/Business+Wire/Delcath+Systems+Reports+Second+Quarter+2026+Results+and+Business+Highlights/26879259.html <p class="bwalignc"> <i>Increases 2026 Revenue Guidance to a Range of $104M to $108M <br></br></i><i>Conference Call Today at 8:30 a.m. Eastern Time</i> </p> <p> QUEENSBURY, N.Y.--(BUSINESS WIRE)-- Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic liver cancers, today announced financial results and business highlights for the second quarter ended June 30, 2026. </p><p> <b>Second Quarter 2026 Financial Results</b> </p><ul class="bwlistdisc"> <li> Total revenue of $29.1 million, compared with $24.2 million in the second quarter of 2025 <ul class="bwlistcircle"> <li> HEPZATO KIT™ revenue of $27.1 million, compared to $22.5 million in the second quarter of 2025 </li> <li> CHEMOSAT® revenue of $2.0 million, compared to $1.7 http://www.streetinsider.com/Business+Wire/Delcath+Systems+Reports+Second+Quarter+2026+Results+and+Business+Highlights/26879259.html Thu, 06 Aug 2026 08:01:00 -0400 A.09642568 DCTH O.02931219 O.20371933 http://www.streetinsider.com/Business+Wire/Delcath+Systems+Reports+Second+Quarter+2026+Results+and+Business+Highlights/26879259.html <p class="bwalignc"> <i>Increases 2026 Revenue Guidance to a Range of $104M to $108M <br></br></i><i>Conference Call Today at 8:30 a.m. Eastern Time</i> </p> <p> QUEENSBURY, N.Y.--(BUSINESS WIRE)-- Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic liver cancers, today announced financial results and business highlights for the second quarter ended June 30, 2026. </p><p> <b>Second Quarter 2026 Financial Results</b> </p><ul class="bwlistdisc"> <li> Total revenue of $29.1 million, compared with $24.2 million in the second quarter of 2025 <ul class="bwlistcircle"> <li> HEPZATO KIT™ revenue of $27.1 million, compared to $22.5 million in the second quarter of 2025 </li> <li> CHEMOSAT® revenue of $2.0 million, compared to $1.7 http://www.streetinsider.com/Business+Wire/Delcath+Systems+Reports+Second+Quarter+2026+Results+and+Business+Highlights/26879259.html Thu, 06 Aug 2026 08:01:00 -0400 A.09642568 DCTH O.02931219 O.20371933 http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13G++DELCATH+SYSTEMS%2C+INC.++++++++++++++++++Filed+by%3A+BlackRock%2C+Inc./26827894.html si-local-file:///var/storage/secattach/20260728/26827894.html http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13G++DELCATH+SYSTEMS%2C+INC.++++++++++++++++++Filed+by%3A+BlackRock%2C+Inc./26827894.html Tue, 28 Jul 2026 16:45:00 -0400 DCTH O.02931219 http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13G++DELCATH+SYSTEMS%2C+INC.++++++++++++++++++Filed+by%3A+BlackRock%2C+Inc./26827894.html si-local-file:///var/storage/secattach/20260728/26827894.html http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13G++DELCATH+SYSTEMS%2C+INC.++++++++++++++++++Filed+by%3A+BlackRock%2C+Inc./26827894.html Tue, 28 Jul 2026 16:45:00 -0400 DCTH O.02931219 http://www.streetinsider.com/Press+Releases/Delcath+Systems+to+Participate+at+the+Canaccord+Genuity+46th+Annual+Growth+Conference/26826829.html <p> QUEENSBURY, N.Y.--(BUSINESS WIRE)-- Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, today announced that management will be attending the Canaccord Genuity 46th Annual Growth Conference on Tuesday, August 11, 2026, in Boston, MA. </p><p> <b>About Delcath Systems, Inc., HEPZATO KIT and CHEMOSAT <br /></b>Delcath Systems, Inc. is an interventional oncology company focused on the treatment of primary and metastatic liver cancers. The company's proprietary products, HEPZATO KIT™ (HEPZATO (melphalan) for Injection/Hepatic Delivery System) and CHEMOSAT® Hepatic Delivery System for Melphalan percutaneous hepatic perfusion (PHP), are designed to http://www.streetinsider.com/Press+Releases/Delcath+Systems+to+Participate+at+the+Canaccord+Genuity+46th+Annual+Growth+Conference/26826829.html Tue, 28 Jul 2026 16:01:00 -0400 DCTH O.02931219 http://www.streetinsider.com/Press+Releases/Delcath+Systems+to+Participate+at+the+Canaccord+Genuity+46th+Annual+Growth+Conference/26826829.html <p> QUEENSBURY, N.Y.--(BUSINESS WIRE)-- Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, today announced that management will be attending the Canaccord Genuity 46th Annual Growth Conference on Tuesday, August 11, 2026, in Boston, MA. </p><p> <b>About Delcath Systems, Inc., HEPZATO KIT and CHEMOSAT <br /></b>Delcath Systems, Inc. is an interventional oncology company focused on the treatment of primary and metastatic liver cancers. The company's proprietary products, HEPZATO KIT™ (HEPZATO (melphalan) for Injection/Hepatic Delivery System) and CHEMOSAT® Hepatic Delivery System for Melphalan percutaneous hepatic perfusion (PHP), are designed to http://www.streetinsider.com/Press+Releases/Delcath+Systems+to+Participate+at+the+Canaccord+Genuity+46th+Annual+Growth+Conference/26826829.html Tue, 28 Jul 2026 16:01:00 -0400 DCTH O.02931219 http://www.streetinsider.com/Business+Wire/Delcath+Systems+to+Participate+at+the+Canaccord+Genuity+46th+Annual+Growth+Conference/26826829.html <p> QUEENSBURY, N.Y.--(BUSINESS WIRE)-- Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, today announced that management will be attending the Canaccord Genuity 46th Annual Growth Conference on Tuesday, August 11, 2026, in Boston, MA. </p><p> <b>About Delcath Systems, Inc., HEPZATO KIT and CHEMOSAT <br /></b>Delcath Systems, Inc. is an interventional oncology company focused on the treatment of primary and metastatic liver cancers. The company's proprietary products, HEPZATO KIT™ (HEPZATO (melphalan) for Injection/Hepatic Delivery System) and CHEMOSAT® Hepatic Delivery System for Melphalan percutaneous hepatic perfusion (PHP), are designed to http://www.streetinsider.com/Business+Wire/Delcath+Systems+to+Participate+at+the+Canaccord+Genuity+46th+Annual+Growth+Conference/26826829.html Tue, 28 Jul 2026 16:01:00 -0400 DCTH O.02931219 http://www.streetinsider.com/Business+Wire/Delcath+Systems+to+Participate+at+the+Canaccord+Genuity+46th+Annual+Growth+Conference/26826829.html <p> QUEENSBURY, N.Y.--(BUSINESS WIRE)-- Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, today announced that management will be attending the Canaccord Genuity 46th Annual Growth Conference on Tuesday, August 11, 2026, in Boston, MA. </p><p> <b>About Delcath Systems, Inc., HEPZATO KIT and CHEMOSAT <br /></b>Delcath Systems, Inc. is an interventional oncology company focused on the treatment of primary and metastatic liver cancers. The company's proprietary products, HEPZATO KIT™ (HEPZATO (melphalan) for Injection/Hepatic Delivery System) and CHEMOSAT® Hepatic Delivery System for Melphalan percutaneous hepatic perfusion (PHP), are designed to http://www.streetinsider.com/Business+Wire/Delcath+Systems+to+Participate+at+the+Canaccord+Genuity+46th+Annual+Growth+Conference/26826829.html Tue, 28 Jul 2026 16:01:00 -0400 DCTH O.02931219 http://www.streetinsider.com/Press+Releases/Delcath+Systems+to+Host+Second+Quarter+2026+Earnings+Call/26807844.html <p> QUEENSBURY, N.Y.--(BUSINESS WIRE)-- Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, announced today it will host a conference call on August 6, 2026, at 8:30 AM Eastern Time to discuss results for its second quarter ended June 30, 2026. </p><p> <b>Conference Call Information</b> </p><p> To participate in this event, dial in approximately 5 to 10 minutes before the beginning of the call. </p><p> Event Date: Thursday, August 6, 2026 <br />Time: 8:30 AM Eastern Time </p><p> Participant Numbers: <br />Toll Free: 1-800-717-1738 <br />International: 1-646-307-1865 <br />Webcast: <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Furl.us.m.mimecastprotect.com%2Fs%2FST19CM8EJyF3Np94tJipc8ViMU%3Fdomain%3Dviavid.webcasts.com&amp;esheet=54575804&amp;newsitemid=20260723206368&amp;lan=en-US&amp;anchor=https%3A%2F%2Fviavid.webcasts.com%2Fstarthere.jsp%3Fei%3D1767384%26amp%3Btp_key%3Dcbc23b55c8&amp;index=1&amp;md5=4aa0f441162a53e0d379f3acd472cb69" shape="rect">https://viavid.webcasts.com/starthere.jsp?ei=1767384&amp;tp_key=cbc23b55c8 </a><br />A replay of the http://www.streetinsider.com/Press+Releases/Delcath+Systems+to+Host+Second+Quarter+2026+Earnings+Call/26807844.html Thu, 23 Jul 2026 16:01:00 -0400 DCTH O.02931219 http://www.streetinsider.com/Press+Releases/Delcath+Systems+to+Host+Second+Quarter+2026+Earnings+Call/26807844.html <p> QUEENSBURY, N.Y.--(BUSINESS WIRE)-- Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, announced today it will host a conference call on August 6, 2026, at 8:30 AM Eastern Time to discuss results for its second quarter ended June 30, 2026. </p><p> <b>Conference Call Information</b> </p><p> To participate in this event, dial in approximately 5 to 10 minutes before the beginning of the call. </p><p> Event Date: Thursday, August 6, 2026 <br />Time: 8:30 AM Eastern Time </p><p> Participant Numbers: <br />Toll Free: 1-800-717-1738 <br />International: 1-646-307-1865 <br />Webcast: <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Furl.us.m.mimecastprotect.com%2Fs%2FST19CM8EJyF3Np94tJipc8ViMU%3Fdomain%3Dviavid.webcasts.com&amp;esheet=54575804&amp;newsitemid=20260723206368&amp;lan=en-US&amp;anchor=https%3A%2F%2Fviavid.webcasts.com%2Fstarthere.jsp%3Fei%3D1767384%26amp%3Btp_key%3Dcbc23b55c8&amp;index=1&amp;md5=4aa0f441162a53e0d379f3acd472cb69" shape="rect">https://viavid.webcasts.com/starthere.jsp?ei=1767384&amp;tp_key=cbc23b55c8 </a><br />A replay of the http://www.streetinsider.com/Press+Releases/Delcath+Systems+to+Host+Second+Quarter+2026+Earnings+Call/26807844.html Thu, 23 Jul 2026 16:01:00 -0400 DCTH O.02931219